MiR-613: a novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma.

Autor: Guan S; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Wang C; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Chen X; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Liu B; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Tan B; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Liu F; Department of Image, Shandong Medical College, Jinan, Shandong, 250002, People's Republic of China., Wang D; Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Han L; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Wang L; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Huang X; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Wang J; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Yao B; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Shi J; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Chen P; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Nesa EU; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Song Q; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China., Cheng Y; Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, People's Republic of China. qlchengyufeng@163.com.
Jazyk: angličtina
Zdroj: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2016 Apr; Vol. 37 (4), pp. 4383-91. Date of Electronic Publication: 2015 Oct 24.
DOI: 10.1007/s13277-015-4271-8
Abstrakt: MicroRNA-613 (miR-613) plays important roles in tumorigenesis and cancer progression. We aimed to evaluate its expression level and potential for diagnosis and prognosis in esophageal squamous cell cancer (ESCC). We examined miR-613 expression in 60 pairs of ESCC cancerous and matched paracancerous tissues, serum samples from 75 ESCC patients and 75 healthy volunteers, and 105 formalin-fixed paraffin-embedded (FFPE) tissue samples using quantitative reverse transcription polymerase chain reaction. Receiver-operating characteristic (ROC) curve analysis, Kaplan-Meier method, and Cox regression were applied to analyze its diagnostic and prognostic value. MiR-613 was significantly decreased in ESCC tissue compared with paracancerous tissue (P < 0.001). Moreover, the expression level of miR-613 was significantly reduced with increased T stage of ESCC. Statistically significant difference between ESCC patients and healthy controls in expression level of miR-613 (0.89 ± 0.73 vs. 1.71 ± 1.03, P < 0.001) was found. The area under the ROC curve (AUC) based on serum miR-613 was 0.767 ± 0.040. We also performed analysis on early-stage patients and revealed that the AUC value was 0.728 ± 0.052 (P < 0.001). The Kaplan-Meier curve revealed that the downregulation of miR-613 was related to worse overall survival (OS) and progression-free survival (PFS) of ESCC patients (P = 0.018 and P = 0.035, respectively). Furthermore, the multivariate analysis identified miR-613 to be an independent prognostic factor for OS and PFS (P = 0.031 and P = 0.006, respectively) In conclusion, miR-613 is significantly reduced in cancerous tissue and serum samples of ESCC patients. It can serve as an ideal indicator for the diagnosis and prognosis of ESCC.
Databáze: MEDLINE
Externí odkaz: